TABLE 1.
Clinical outcomes of patients undergoing EVT according to quartiles of leukocyte counts (×109/L), neutrophil counts (×109/L), and NLR.
| Outcomes, n/total (%) | Leukocyte (×109/L) |
Neutrophil (×109/L) |
NLR |
||||||||||||
| <8.40 | 8.40–11.06 | 11.06–13.66 | >13.66 | p value | <6.60 | 6.60–9.15 | 9.15–11.96 | >11.96 | p value | <4.96 | 4.96–7.93 | 7.93–12.63 | >12.63 | p value | |
| mRS 0-2 at 90d | 62(42.2) | 42(28.6) | 29(19.9) | 28(19.2) | <0.001a | 64(43.5) | 39(26.5) | 33(22.6) | 25(17.1) | <0.001d | 59(40.4) | 42(28.4) | 34(23.3) | 26(17.8) | <0.001g |
| mRS 0-3 at 90d | 71(48.3) | 49(33.3) | 37(25.3) | 32(21.9) | <0.001b | 74(50.3) | 44(29.9) | 42(28.8) | 29(19.9) | <0.001e | 66(45.2) | 56(37.8) | 36(24.7) | 31(21.2) | <0.001h |
| Mortality at 90d | 50(34.0) | 62(42.2) | 67(45.9) | 81(55.5) | 0.003c | 48(32.7) | 66(44.9) | 64(43.8) | 82(56.2) | 0.001f | 48 | 64 | 72 | 76 | 0.005i |
aPairwise comparisons: adjusted p < 0.05 for comparisons between <8.40 and >13.66, between <8.40 and 11.06–13.66.
bPairwise comparisons: adjusted p < 0.05 for comparisons between <8.40 and >13.66, between <8.40 and 11.06–13.66.
cPairwise comparisons: adjusted p < 0.05 for comparisons between <8.40 and >13.66.
dPairwise comparisons.
ePairwise comparisons: adjusted p < 0.05 for comparisons between <6.60 and 6.60–9.15, between <6.60 and 9.15–11.96, between <6.60 and >11.96.
fPairwise comparisons: adjusted p < 0.05 for comparisons between <6.60 and >11.96.
gPairwise comparisons: adjusted p < 0.05 for comparisons between <4.96 and 7.93–12.63, between <4.96 and >12.63.
hPairwise comparisons: adjusted p < 0.05 for comparisons between <4.96 and 7.93–12.63, between <4.96 and >12.63, between 4.96–7.93 and >12.63.
iPairwise comparisons: adjusted p < 0.05 for comparisons between <4.96 and 7.93–12.63, between <4.96 and >12.63. EVT, endovascular treatment; NLR, neutrophil-to-lymphocyte ratio; mRS, modified Rankin Scale.